Disease landscape

Kidney Cancer clinical trials

Get alerts when Kidney Cancer trials change

547 active trials 310 recruiting 39 Phase 3 317 sponsors 75 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 46 of 75 changes on 20 trials

2026-09-05
Primary completion pushed: 2026-04-30 → 2026-12-30
Completion pushed: 2026-06-30 → 2026-12-30
NCT04707248 A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors · Daiichi Sankyo · Phase 1
2026-09-05
Primary completion pushed: 2027-08-30 → 2028-12-31
Recruitment opened
Completion pushed: 2027-08-30 → 2028-12-31
NCT07516366 Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab… · National Cancer Institute (NCI) · Phase 2
2026-09-01
Primary completion pushed: 2025-10-07 → 2026-08-06
Completion pushed: 2026-12-31 → 2027-08-31
NCT04006522 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal… · James Brugarolas · Phase 2
2026-09-04
Primary completion pushed: 2026-09 → 2027-09
Completion pushed: 2027-01 → 2028-01
NCT06138067 Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-09-03
Primary completion pushed: 2026-07-24 → 2027-07-24
Completion pushed: 2026-07-24 → 2027-07-24
NCT05837767 A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue · Memorial Sloan Kettering Cancer Center
2026-09-03
Primary endpoint(s) modified
Trial completed
Primary completion confirmed: June 2026 (last estimated June 2027)
NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in… · Sensei Biotherapeutics, Inc. · Phase 1/2
2026-08-21
Primary completion pushed: 2026-10-01 → 2027-10-01
Completion pushed: 2028-02-01 → 2028-04-01
NCT07123090 A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Stephanie Berg · Phase 2
2026-08-20
Primary completion pushed: 2026-10-01 → 2027-10-01
Completion pushed: 2027-07-01 → 2028-07-01
NCT05361720 Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney… · Vanderbilt-Ingram Cancer Center · Phase 2
2026-08-14
Primary completion pushed: 2026-06 → 2028-04
Completion pushed: 2028-01 → 2028-12
NCT05733715 Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma · Abramson Cancer Center at Penn Medicine · Early Phase 1
2026-08-20
Primary completion pushed: 2026-06-15 → 2026-10-01
Completion pushed: 2026-06-15 → 2026-10-01
NCT04788095 App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients… · City of Hope Medical Center
2026-08-26
Primary endpoint(s) modified
NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… · Lumina Pharmaceuticals Inc · Early Phase 1
2026-08-22
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 56 → 299 participants
Trial sites expanded: 0 → 3 locations
Primary completion moved earlier: 2028-08 → 2027-08
Trial arms changed: 2 → 3
NCT07623369 A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · Huahui Health · Phase 1
2026-09-01
Primary endpoint(s) modified
Phase changed: Phase 2 → not applicable
Trial completed
Results posted: 2026-08-31
Primary completion confirmed: January 2024 (last estimated December 2025)
NCT02956798 SAbR For Oligometastatic Renal Cell Carcinoma · University of Texas Southwestern Medical Center
2026-08-21
Primary endpoint(s) modified
Trial arms changed: 4 → 5
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for… · Mayo Clinic · Phase 1/2
2026-08-12
Enrollment reduced: 139 → 92 participants
Trial arms changed: 3 → 2
NCT07239596 Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of… · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase 1/2
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Genentech, Inc. · Phase 1
2026-08-09
Sponsor changed: ITM Oncologics GmbH → Lumara Bio Oncologics GmbH
NCT05706129 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452… · Lumara Bio Oncologics GmbH · Phase 1/2
2026-08-25
Trial completed
Completion pushed: 2026-01-16 → 2026-04-01
NCT03141177 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously… · Bristol-Myers Squibb · Phase 3
2026-08-19
Enrolling by invitation only
NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… · Exelixis · Phase 3
2026-08-20
Recruitment opened
NCT07636785 A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors · VM Discovery, Inc. · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-04 NCT07805122 Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management… Centro di Riferimento Oncologico - Aviano new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-24 NCT07782164 Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) Amsterdam UMC, location VUmc new
2026-08-18 NCT07770802 Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer Qingdao Sino-Cell Biomedicine Co., Ltd. new Phase 1
2026-08-17 NCT07768306 Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and… Norroy Bioscience Co., LTD new Phase 1
2026-08-04 NCT07744932 SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma Hebei Medical University Fourth Hospital new Phase 2
2026-07-20 NCT07715565 Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced… West China Hospital new Phase 2
2026-07-20 NCT07713654 Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct… University of Zurich new
2026-07-15 NCT07704970 QLESP Block for Pain Control in Robotic Partial Nephrectomy Huazhong University of Science and Technology new
2026-07-08 NCT07689812 A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus… Natera, Inc. new

Active trials by phase

Early Phase 1
10
Phase 1
97
Phase 1/2
59
Phase 2
142
Phase 2/3
3
Phase 3
36
Phase 4
6
Not charted: 194 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 547

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07028125 Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus… Centre Francois Baclesse Recruiting 2026-07-14
NCT07405086 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… OHSU Knight Cancer Institute Recruiting 2026-06-12
NCT06934057 Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma Gustave Roussy, Cancer Campus, Grand Paris Recruiting 2025-09-24
NCT06903312 Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With… Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting 2025-07-03
NCT05805436 Preop Laxatives in Robotic Urologic Surgery Chad R. Tracy Recruiting 2025-05-30
NCT07802847 Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and… Gustave Roussy, Cancer Campus, Grand Paris Not Yet Recruiting 2026-09-03
Phase 3
NCT06661720 Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab)… Alliance for Clinical Trials in Oncology Recruiting 2026-09-02
NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… Arcus Biosciences, Inc. Recruiting 2026-09-02
NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients… NRG Oncology Recruiting 2026-08-17
NCT07227402 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer… Merck Sharp & Dohme LLC Recruiting 2026-08-03
NCT07092566 R.E.C.K vs Exparel in Robotic Nephrectomy Wake Forest University Health Sciences Recruiting 2026-07-13
NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer SWOG Cancer Research Network Recruiting 2026-06-11
NCT07197580 Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or… Telix Pharmaceuticals (Innovations) Pty Limited Recruiting 2026-04-01
NCT05738694 Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal… ZHOU FANGJIAN Recruiting 2026-03-17
NCT06349668 Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery Hans Bahlmann Recruiting 2026-02-05
NCT06726421 Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney… Sun Yat-sen University Recruiting 2026-01-15
NCT04510597 Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without… SWOG Cancer Research Network Recruiting 2025-09-09
NCT05796973 Measuring Oncological Value of Exercise and Statin Tampere University Hospital Recruiting 2025-06-27
NCT03592472 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or… Xynomic Pharmaceuticals, Inc. Recruiting 2025-04-13
NCT06364631 CARE1 Pragmatic Clinical Trial Gustave Roussy, Cancer Campus, Grand Paris Recruiting 2025-01-16
NCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study Telix Pharmaceuticals (Innovations) Pty Limited Recruiting 2024-12-27
NCT03288532 Renal Adjuvant MultiPle Arm Randomised Trial University College, London Recruiting 2020-09-07
NCT03793166 Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With… National Cancer Institute (NCI) Active, Not Recruiting 2026-08-31
NCT03055013 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy National Cancer Institute (NCI) Active, Not Recruiting 2026-08-28
NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… Exelixis Enrolling by Invitation 2026-08-18
See all 547 active Kidney Cancer trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (24) · National Cancer Institute (NCI) (24) · Memorial Sloan Kettering Cancer Center (13) · City of Hope Medical Center (10) · Sun Yat-sen University (9) · Jinling Hospital, China (7) · Mayo Clinic (7) · RenJi Hospital (7) · University of Texas Southwestern Medical Center (7) · AstraZeneca (6)

Get alerts when Kidney Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free